Skip to main content

Peptide Therapeutic Deal Benchmarks in Neurology

Median Upfront
$361M
Range: $179M - $545M
Total Deal Value
$3.2B
Range: $1.9B - $4.5B
Royalty Rate
12.5% - 20.1%
Tiered up to 24.1%
Dev Milestones
$934M
Range: $573M - $1.3B
Model Your Deal

Market Analysis

Peptide Therapeutic therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 peptide therapeutic asset in neurology is $361M, with total deal values reaching $3.2B. Development milestones average $934M, while regulatory milestones contribute $1.0B.

The neurology peptide therapeutic landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for peptide therapeutic neurology deals range from 12.5% to 20.1% at the base tier, with tiered escalation reaching 16.5%-24.1% on blockbuster sales. Commercial milestones averaging $877M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a peptide therapeutic neurology licensing deal?
Based on our analysis, Phase 2 peptide therapeutic licensing deals in neurology average $361M in upfront payments, with a range of $179M to $545M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for peptide therapeutic neurology transactions?
The median total deal value for Phase 2 peptide therapeutic assets in neurology is $3.2B, ranging from $1.9B to $4.5B. This includes development milestones ($934M), regulatory milestones ($1.0B), and commercial milestones ($877M).
What royalty rates are standard for peptide therapeutic deals in neurology?
Base royalty rates for peptide therapeutic neurology transactions range from 12.5% to 20.1%, with tiered escalations reaching 16.5%-24.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in peptide therapeutic neurology deals?
Peptide Therapeutic neurology deals allocate approximately 89% of total deal value to milestones. Development milestones ($934M) make up the largest share, followed by commercial milestones ($877M) and regulatory milestones ($1.0B).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Neurology

View

Monoclonal Antibody in Neurology

View

Peptide Therapeutic in Oncology

View

Peptide Therapeutic in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included